BCEL - Atreca, Inc.

NasdaqGS - NasdaqGS Real Time Price. Currency in USD
+0.36 (+2.33%)
At close: 4:00PM EDT
Stock chart is not supported by your current browser
Previous Close15.48
Bid15.66 x 800
Ask17.40 x 800
Day's Range15.18 - 16.38
52 Week Range14.26 - 20.00
Avg. Volume243,866
Market Cap424.266M
Beta (3Y Monthly)N/A
PE Ratio (TTM)N/A
EPS (TTM)-3.46
Earnings DateN/A
Forward Dividend & YieldN/A (N/A)
Ex-Dividend DateN/A
1y Target Est25.50
Trade prices are not sourced from all markets
  • Benzinga3 days ago

    Stifel: Atreca Offers Attractive Oncology Drug Development Play

    Atreca has a highly differentiated approach to antibody drug discovery that moves completely away from the biologically or genetically derived hypotheses that are traditionally used to inform target selection, Willey said in a Monday initiation note.

  • GlobeNewswire7 days ago

    Atreca Further Strengthens Management Team with Appointment of Lisa Decker as Chief Business Officer and Courtney Phillips as General Counsel

    Atreca, Inc. (NASDAQ: BCEL), a biotechnology company focused on developing novel therapeutics based on a deep understanding of the human immune response, today announced the appointment of Lisa L. Decker, Ph.D., as Chief Business Officer and Courtney J. Phillips as General Counsel. As Chief Business Officer, Dr. Decker will lead Atreca’s corporate development function, including its strategic partnering initiatives and alliance management.

  • Benzinga28 days ago

    Atreca Opens For Trade

    Atreca, Inc. (NASDAQ: BCEL ) shares opened for trade Thursday morning at $19.90. The IPO of 7.35 million shares was priced at $17. Atreca is a biopharma company that uses its platform to discover and develop ...

  • GlobeNewswire28 days ago

    Atreca Announces Pricing of Initial Public Offering

    REDWOOD CITY, Calif., June 19, 2019 -- Atreca, Inc. (Nasdaq: BCEL), a biopharmaceutical company utilizing its differentiated platform to discover and develop novel.

  • Benzinga29 days ago

    Atreca IPO: What You Need To Know

    Cancer biotechs are the hottest among drug development companies, given the lucrative market opportunity before them. One such company is testing the IPO waters this week. The IPO Terms Redwood, California-based ...

  • Benzingalast month

    IPO Outlook For The Week: Biotechs And A Grocery Outlet

    For a more comprehensive IPO calendar, check out the offering in Benzinga Cloud . The IPO dates below are expected but not confirmed. Stoke Therapeutics, Inc. (STOK) will issue 6.7 million shares between ...